目的 了解应用粒细胞巨噬细胞刺激因子(GM-CSF)对大鼠创面愈合的影响及对哺乳动物西罗莫司(雷帕霉素)靶蛋白(mTOR)信号通路的作用. 方法 将50只SD大鼠按照随机数字表法分为治疗组和对照组,每组25只,于其背部制作约2 cm×2 cm全层皮肤缺损创面.治疗组大鼠创面外涂重组人粒细胞巨噬细胞刺激因子( rhGM-CSF)凝胶,10 μg/cm2,rhGM-CSF实际作用量为1×10-4 μg/cm2;对照组创面涂抹不含任何药物的凝胶基质,10 μg/cm2.2组每日给药1次直至创面愈合.于致伤后1、3、5、7、14 d,每组每时相点处死5只大鼠:(1)观察并计算创面愈合率.(2)于前4个时相点取创面组织标本,行HE染色观察组织病理学改变,ELISA法检测GM-CSF含量,蛋白质印迹法检测GM-CSF、CD31及mTOR信号通路相关分子P70S6K、磷酸化(p-)P70S6K、4E-BP1、p-4E-BP1、mTOR、p-mTOR表达量.对数据行t检验. 结果 (1)伤后1d,2组大鼠创面愈合率接近(t=0.307,P>0.05);伤后3~ 14 d,治疗组创面愈合率明显高于对照组(t值为2.704~ 4.030,P <0.05或P <0.01).(2)HE染色可见,与对照组同时相点相比,治疗组创面肉芽组织及微血管数量明显增多,创缘角化上皮细胞增殖明显.(3)ELISA法和蛋白质印迹检测结果显示,2组大鼠创面GM-CSF含量及蛋白表达量均在伤后3d达到峰值,对照组分别为(720.9±0.9)pg/mL、2.45±0.10,治疗组分别为(910.5±1.3)pg/mL、2 80±0.48.治疗组各时相点GM-CSF含量均明显高于对照组(t值为105.743~298.971,P值均为0.000),治疗组伤后1、5、7 d GM-CSF蛋白表达量明显高于对照组(t值为4.070~5.275,P值均小于0.01).(4)治疗组伤后1、3、7d创面组织中CD31表达量均明显高于对照组(t值为7.237~26.401,P值均小于0.01).(5)治疗组伤后各时相点创面组织中mTOR和p-mTOR表达量均高于对照组(t值为2.921 ~23.143,P <0.05或P<0.01).治疗组P70S6K表达量伤后3、5、7d高于对照组(t值为2.950~5.275,P<0 05或P<0.01),p-P70S6K表达量于伤后1、3、7d高于对照组(t值为3.307 ~22.793,P<0.05或P<0.01).治疗组伤后1、3、5 d 4E-BP1表达量均明显低于对照组(t值为2.449~6.431,P<0.05或P<0.01),p-4E-BP1表达量于伤后1、3、7 d高于对照组(t值为5.522~11.613,P值均小于0.01). 结论 GM-CSF能促进大鼠创面组织mTOR蛋白及其下游信号分子P70S6K、4E-BP1的磷酸化,从而激活mTOR信号通路,促进创面愈合.
目的 瞭解應用粒細胞巨噬細胞刺激因子(GM-CSF)對大鼠創麵愈閤的影響及對哺乳動物西囉莫司(雷帕黴素)靶蛋白(mTOR)信號通路的作用. 方法 將50隻SD大鼠按照隨機數字錶法分為治療組和對照組,每組25隻,于其揹部製作約2 cm×2 cm全層皮膚缺損創麵.治療組大鼠創麵外塗重組人粒細胞巨噬細胞刺激因子( rhGM-CSF)凝膠,10 μg/cm2,rhGM-CSF實際作用量為1×10-4 μg/cm2;對照組創麵塗抹不含任何藥物的凝膠基質,10 μg/cm2.2組每日給藥1次直至創麵愈閤.于緻傷後1、3、5、7、14 d,每組每時相點處死5隻大鼠:(1)觀察併計算創麵愈閤率.(2)于前4箇時相點取創麵組織標本,行HE染色觀察組織病理學改變,ELISA法檢測GM-CSF含量,蛋白質印跡法檢測GM-CSF、CD31及mTOR信號通路相關分子P70S6K、燐痠化(p-)P70S6K、4E-BP1、p-4E-BP1、mTOR、p-mTOR錶達量.對數據行t檢驗. 結果 (1)傷後1d,2組大鼠創麵愈閤率接近(t=0.307,P>0.05);傷後3~ 14 d,治療組創麵愈閤率明顯高于對照組(t值為2.704~ 4.030,P <0.05或P <0.01).(2)HE染色可見,與對照組同時相點相比,治療組創麵肉芽組織及微血管數量明顯增多,創緣角化上皮細胞增殖明顯.(3)ELISA法和蛋白質印跡檢測結果顯示,2組大鼠創麵GM-CSF含量及蛋白錶達量均在傷後3d達到峰值,對照組分彆為(720.9±0.9)pg/mL、2.45±0.10,治療組分彆為(910.5±1.3)pg/mL、2 80±0.48.治療組各時相點GM-CSF含量均明顯高于對照組(t值為105.743~298.971,P值均為0.000),治療組傷後1、5、7 d GM-CSF蛋白錶達量明顯高于對照組(t值為4.070~5.275,P值均小于0.01).(4)治療組傷後1、3、7d創麵組織中CD31錶達量均明顯高于對照組(t值為7.237~26.401,P值均小于0.01).(5)治療組傷後各時相點創麵組織中mTOR和p-mTOR錶達量均高于對照組(t值為2.921 ~23.143,P <0.05或P<0.01).治療組P70S6K錶達量傷後3、5、7d高于對照組(t值為2.950~5.275,P<0 05或P<0.01),p-P70S6K錶達量于傷後1、3、7d高于對照組(t值為3.307 ~22.793,P<0.05或P<0.01).治療組傷後1、3、5 d 4E-BP1錶達量均明顯低于對照組(t值為2.449~6.431,P<0.05或P<0.01),p-4E-BP1錶達量于傷後1、3、7 d高于對照組(t值為5.522~11.613,P值均小于0.01). 結論 GM-CSF能促進大鼠創麵組織mTOR蛋白及其下遊信號分子P70S6K、4E-BP1的燐痠化,從而激活mTOR信號通路,促進創麵愈閤.
목적 료해응용립세포거서세포자격인자(GM-CSF)대대서창면유합적영향급대포유동물서라막사(뢰파매소)파단백(mTOR)신호통로적작용. 방법 장50지SD대서안조수궤수자표법분위치료조화대조조,매조25지,우기배부제작약2 cm×2 cm전층피부결손창면.치료조대서창면외도중조인립세포거서세포자격인자( rhGM-CSF)응효,10 μg/cm2,rhGM-CSF실제작용량위1×10-4 μg/cm2;대조조창면도말불함임하약물적응효기질,10 μg/cm2.2조매일급약1차직지창면유합.우치상후1、3、5、7、14 d,매조매시상점처사5지대서:(1)관찰병계산창면유합솔.(2)우전4개시상점취창면조직표본,행HE염색관찰조직병이학개변,ELISA법검측GM-CSF함량,단백질인적법검측GM-CSF、CD31급mTOR신호통로상관분자P70S6K、린산화(p-)P70S6K、4E-BP1、p-4E-BP1、mTOR、p-mTOR표체량.대수거행t검험. 결과 (1)상후1d,2조대서창면유합솔접근(t=0.307,P>0.05);상후3~ 14 d,치료조창면유합솔명현고우대조조(t치위2.704~ 4.030,P <0.05혹P <0.01).(2)HE염색가견,여대조조동시상점상비,치료조창면육아조직급미혈관수량명현증다,창연각화상피세포증식명현.(3)ELISA법화단백질인적검측결과현시,2조대서창면GM-CSF함량급단백표체량균재상후3d체도봉치,대조조분별위(720.9±0.9)pg/mL、2.45±0.10,치료조분별위(910.5±1.3)pg/mL、2 80±0.48.치료조각시상점GM-CSF함량균명현고우대조조(t치위105.743~298.971,P치균위0.000),치료조상후1、5、7 d GM-CSF단백표체량명현고우대조조(t치위4.070~5.275,P치균소우0.01).(4)치료조상후1、3、7d창면조직중CD31표체량균명현고우대조조(t치위7.237~26.401,P치균소우0.01).(5)치료조상후각시상점창면조직중mTOR화p-mTOR표체량균고우대조조(t치위2.921 ~23.143,P <0.05혹P<0.01).치료조P70S6K표체량상후3、5、7d고우대조조(t치위2.950~5.275,P<0 05혹P<0.01),p-P70S6K표체량우상후1、3、7d고우대조조(t치위3.307 ~22.793,P<0.05혹P<0.01).치료조상후1、3、5 d 4E-BP1표체량균명현저우대조조(t치위2.449~6.431,P<0.05혹P<0.01),p-4E-BP1표체량우상후1、3、7 d고우대조조(t치위5.522~11.613,P치균소우0.01). 결론 GM-CSF능촉진대서창면조직mTOR단백급기하유신호분자P70S6K、4E-BP1적린산화,종이격활mTOR신호통로,촉진창면유합.
Objective To investigate the effects of granulocyte-macrophage colony-stimulating factor (GM-CSF)on wound healing and mammalian target of sirolimus(rapamycin)signaling pathway in rats.Methods Fifty SD rats were divided into control group( n =25 )and treatment group( n =25)according to the random number table.All rats were inflicted with 2 cm × 2 cm full-thickness skin wound on the back.Recombinant human GM-CSF gel(10 μg/cm2)was applied onto the wounds in treatment group,and the actual quantity was 1 × 10-4 μg/cm2.Gel vehicle( 10 μg/cm2 )without any medicine was applied onto the wounds in control group.The treatment was conducted once a day up to the day of wound healing.Five rats from two groups were sacrificed on post injury day(PID)1,3,5,7,14 respectively to observe and determine the wound healing rate.Wound tissue samples were collected at the former 4 time points to observe the histopathological changes with HE staining,and to detect the content of GM-CSF with enzyme-linked immunosorbent assay,and the expression levels of GM-CSF,CD31,and the mTOR signal pathway associated molecules P70S6K,phosphorylated(p-)P70S6K,4E-BP1,p-4E-BP1,mTOR,p-mTOR with Western blotting.Data were processed with t test. Results ( 1 )Wound healing rates in control group and treatment group were close on PID 1( t =0.307,P > 0.05 ).Wound healing rate in treatment group was obviously higher than that in control group on PID 3,5,7,and 14( with t values from 2.704 to 4.030,P <0.05 or P< 0.01 ).(2)Compared with those in control group,more abundant granulation tissue was observed in treatment group,in which an increase in the number of microveseels and obvious proliferation of keratinized epithelial cells in wound margin were observed at each time point.(3)The content and the protein expression level of GM-CSF peaked on PID 3 in two groups,and they were(720.9 ± 0.9)pg/mL,2.45 ±0.10 in control group and(910.5 ± 1.3)pg/mL,2.80 ± 0.48 in treatment group.The content of GM-CSF in treatment group was significantly higher than that in control group at each time point( with t values from 105.743 to 298.971,P values all equal to 0.000).The protein expression level of GM-CSF in treatment group was significantly higher than that in control group on PID 1,5,and 7( with t values from 4.070 to 5.275,P values all below 0.01 ).(4)The expression level of CD31 in treatment group was obviously higher than that in control group on PID 1,3,and 7( with t values from 7.237 to 26.401,P values allbelow 0.01 ).(5)The expression levels of mTOR and p-mTOR in treatment group were significantly higher than those in control group at each time point(with t values from 2.921 to 23.143,P < 0.05 or P < 0.01 ).In treatment group,the expression level of P70S6K was obviously higher than that in control group on PID 3,5,and 7(with t values from 2.950 to 5.275,P < 0.05 or P < 0.01 ),and the expression level of pP70S6K was significantly higher than that in control group on PID 1,3,and 7( with t values from 3.307 to 22.793,P < 0.05 or P < 0.01 ).In treatment group,the expression level of4E-BP1 was significantly lower than that in control group on PID 1,3,and 5( with t values from 2.449 to 6.431,P < 0.05 or P < 0.01 ),but the expression level of p-4E-BP1 was significantly higher than that in control group on PID 1,3,and 7 (with t values from 5.522 to 11.613,P values all below 0.01 ). Conclusions GM-CSF can promote wound healing in rats by activating mTOR signaling pathway through phosphorylating mTOR proteins and its downstream signal molecules P70S6K and 4E-BP1.